Antiphospholipid Syndrome Novel Therapies - European Medical Journal

Antiphospholipid Syndrome Novel Therapies

Download PDF
Mohamad Bittar, *Imad Uthman

No potential conflict of interest.

EMJ Rheumatol. ;1[1]:113-121. DOI/10.33590/emjrheumatol/10312311.
Antiphospholipid syndrome, thrombosis, antiphospholipid antibodies, seronegative antiphospholipid syndrome, thromboprophylaxis, immunomodulatory, new oral anticoagulants.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.


Antiphospholipid syndrome (APS) is an autoimmune disease characterised by arterial and/or venous thrombosis, recurrent pregnancy loss, and persistently positive antiphospholipid antibodies (aPLs). It could be life-threatening as in the case of catastrophic APS where multi-organ failure is observed. APS morbidities are thought to be the result of a combination of thrombotic and inflammatory processes. Over the past decades, the mainstay of therapy of APS has been anticoagulation. As new mechanisms of pathogenesis are being unravelled with time, novel targeted immunomodulatory therapies are being proposed as promising agents in the treatment of APS. In this article, we present an overview of new pathogenetic mechanisms in APS as well as novel antithrombotic and immunomodulatory therapies.

Please view the full content in the pdf above.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now